Risk factors for outcome in refractory acute myeloid leukemia patients treated with a combination of fludarabine, cytarabine, and amsacrine followed by a reduced-intensity conditioning and allogeneic stem cell transplantation

详细信息    查看全文

• 作者：Christian Pfrepper ; Anne Klink…
• 关键词：Allogeneic stem cell transplantation ; Refractory acute myeloid leukemia ; FLAMSA ; RIC ; Risk factors after allogeneic HCT ; donor lymphocytic infusions ; DLI ; Reduced ; intensity conditioning
• 刊名：Journal of Cancer Research and Clinical Oncology
• 出版年：2016
• 出版时间：January 2016
• 年：2016
• 卷：142
• 期：1
• 页码：317-324
• 全文大小：464 KB
• 参考文献：Breems DA, Van Putten WL, Huijgens PC, Ossenkoppele GJ, Verhoef GE, Verdonck LF et al (2005) Prognostic index for adult patients with acute myeloid leukemia in first relapse. J Clin Oncol 23(9):1969–1978PubMed CrossRef
  Buchholz S, Dammann E, Stadler M, Krauter J, Beutel G, Trummer A et al (2012) Cytoreductive treatment with clofarabine/Ara-C combined with reduced-intensity conditioning and allogeneic stem cell transplantation in patients with high-risk, relapsed, or refractory acute myeloid leukemia and advanced myelodysplastic syndrome. Eur J Hematol 88(1):52–60. doi:10.​1111/​j.​1600-0609.​2011.​01703.​x CrossRef
  Craddock C, Labopin M, Pillai S, Finke J, Bunjes D, Greinix H et al (2011) Factors predicting outcome after unrelated donor stem cell transplantation in primary refractory acute myeloid leukaemia. Leukemia 25(5):808–813. doi:10.​1038/​leu.​2011.​13 PubMed CrossRef
  Döhner H, Estey EH, Amadori S, Appelbaum FR, Büchner T, Burnett AK et al (2010) Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 115(3):453–474. doi:10.​1182/​blood-2009-07-235358 PubMed CrossRef
  Duval M, Klein JP, He W, Cahn JY, Cairo M, Camitta BM et al (2010) Hematopoietic stem-cell transplantation for acute leukemia in relapse or primary induction failure. J Clin Oncol 28(23):3730–3738. doi:10.​1200/​JCO.​2010.​28.​8852 PubMed PubMedCentral CrossRef
  Gray RJ (1988) A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 16:1141–1154CrossRef
  Krejci M, Doubek M, Dusek J, Brychtova Y, Racil Z, Navratil M et al (2013) Combination of fludarabine, amsacrine, and cytarabine followed by reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation in patients with high-risk acute myeloid leukemia. Ann Hematol 92(10):1397–1403. doi:10.​1007/​s00277-013-1790-5 PubMed CrossRef
  Löwenberg B, Downing JR, Burnett A (1999) Acute myeloid leukemia. N Engl J Med 341(14):1051–1062PubMed CrossRef
  Massenkeil G, Nagy M, Lawang M, Rosen O, Genvresse I, Geserick G et al (2003) Reduced intensity conditioning and prophylactic DLI can cure patients with high-risk acute leukaemias if complete donor chimerism can be achieved. Bone Marrow Transplant 31(5):339–345PubMed CrossRef
  Oyekunle AA, Kröger N, Zabelina T, Ayuk F, Schieder H, Renges H et al (2006) Allogeneic stem-cell transplantation in patients with refractory acute leukemia: a long-term follow-up. Bone Marrow Transplant 37(1):45–50PubMed
  Pfeiffer T, Schleuning M, Mayer J, Haude KH, Tischer J, Buchholz S et al (2013) Influence of molecular subgroups on outcome of acute myeloid leukemia with normal karyotype in 141 patients undergoing salvage allogeneic stem cell transplantation in primary induction failure or beyond first relapse. Haematoligca 98(4):518–525. doi:10.​3324/​haematol.​2012.​070235 CrossRef
  Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J et al (1995) Consensus on acute GVHD grading. Bone Marrow Transplant 15(6):825–828PubMed
  Saure C, Schroeder T, Zohren F, Bruns I, Czibere A et al (2012) Upfront allogeneic blood stem cell transplantation for patients with high-risk myelodysplastic syndrome or secondary acute myeloid leukemia using a FLAMSA-based high-dose sequential conditioning regimen. Biol Blood Marrow Transplant 18(3):466–472. doi:10.​1016/​j.​bbmt.​2011.​09.​006 PubMed CrossRef
  Sayer HG, Kröger M, Beyer J, Kiehl M, Klein SA, Schaefer-Eckart K et al (2003) Reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia: disease status by marrow blasts is the strongest prognostic factor. Bone Marrow Transplant 31(12):1089–1095PubMed CrossRef
  Schmid C, Schleuning M, Ledderose G, Tischer J, Kolb HJ (2005) Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome. J Clin Oncol 23(24):5675–5687PubMed CrossRef
  Schmid C, Schleuning M, Schwerdtfeger R, Hertenstein B, Mischak-Weissinger E, Bunjes D et al (2006) Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation. Blood 108(3):1092–1099PubMed CrossRef
  Schmid C, Labopin M, Nagler A, Bornhäuser M, Finke J, Fassas A et al (2007) Donor lymphocyte infusion in the treatment of first hematological relapse after allogeneic stem-cell transplantation in adults with acute myeloid leukemia: a retrospective risk factors analysis and comparison with other strategies by the EBMT Acute Leukemia Working Party. J Clin Oncol 25(31):4938–4945PubMed CrossRef
  Schmid C, Schleuning M, Hentrich M, Markl GE, Gerbitz A, Tischer J et al (2008) High antileukemic efficacy of an intermediate intensity conditioning regimen for allogeneic stem cell transplantation in patients with high-risk acute myeloid leukemia in first complete remission. BMT 41(8):721–727. doi:10.​1038/​sj.​bmt.​1705965
  Schmid C, Schleuning M, Tischer J, Holler E, Haude KH, Braess J et al (2012a) Early allo-SCT for AML with a complex aberrant karyotype–results from a prospective pilot study. Bone Marrow Transplant 47(1):46–53. doi:10.​1038/​bmt.​2011.​15 PubMed CrossRef
  Schmid C, Labopin M, Nagler A, Niederwieser D, Castagna L, Tabrizi R et al (2012b) Treatment, risk factors, and outcome of adults with relapsed AML after reduced intensity conditioning for allogeneic stem cell transplantation. Blood 119(6):1599–1606. doi:10.​1182/​blood-2011-08-375840 PubMed CrossRef
  Schneidawind D, Federmann B, Faul C, Vogel W, Kanz L, Bethge WA (2013) Allogeneic hematopoietic cell transplantation with reduced-intensity conditioning following FLAMSA for primary refractory or relapsed acute myeloid leukemia. Ann Hematol 92(10):1389–1395. doi:10.​1007/​s00277-013-1774-5 PubMed CrossRef
  Scrucca L, Santucci A, Aversa F (2007) Competing risk analysis using R: an easy guide for clinicians. Bone Marrow Transplant 40(4):381–387PubMed CrossRef
  Shulman HM, Sullivan KM, Weiden PL, McDonald GB, Striker GE, Sale GE et al (1980) Chronic graft-versus-host syndrome in man: a long-term clinicopathologic study of 20 Seattle patients. Am J Med 69:204–217PubMed CrossRef
  
• 作者单位：Christian Pfrepper (1)
  Anne Klink (2)
  Gerhard Behre (1)
  Thomas Schenk (2)
  Georg-Nikolaus Franke (1)
  Madlen Jentzsch (1)
  Sebastian Schwind (1)
  Haifa-Kathrin Al-Ali (1)
  Andreas Hochhaus (2)
  Dietger Niederwieser (1)
  Herbert Gottfried Sayer (2) (3)
  
  1. Abteilung für Hämatologie, Internistische Onkologie, Universitätsklinikum Leipzig, 04103, Leipzig, Germany
  2. Klinik für Innere Medizin II, Abteilung für Hämatologie und Internistische Onkologie, Universitätsklinikum Jena, Jena, Germany
  3. 4. Medizinische Klinik (Hämatologie, internistische Onkologie und Hämostaseologie), HELIOS-Klinikum Erfurt, Erfurt, Germany
  
• 刊物类别：Medicine
• 刊物主题：Medicine & Public Health
  Oncology
  Cancer Research
  Internal Medicine
  Hematology
  
• 出版者：Springer Berlin / Heidelberg
• ISSN：1432-1335

文摘

Introduction Hematopoietic stem cell transplantation (HCT) is considered a standard treatment for high-risk acute myeloid leukemia (AML) in first or second complete remission (CR). Unfortunately, not all patients achieve complete remission prior to HCT. We sought to establish predictive factors for survival after HCT for refractory AML after FLAMSA-RIC.